Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COGNITO-MB: Neurocognitive Outcomes in Low-risk Medulloblastoma
NCT07291102Phase 3Not yet recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Jan 2027
- Primary completion
- Oct 2034
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carboplatin, etoposide, Cisplatin micelle injection (HA132), vincristine sulfate liposome injection, cyclophosphamide in medulloblastoma, sponsored by Nationwide Children's Hospital. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
carboplatinetoposideCisplatin micelle injection (HA132)vincristine sulfate liposome injectioncyclophosphamide
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT07291102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07291102.